Antibody against the antigen receptor of a plasmacytoma prolongs survival of mice bearing the tumor.
A transplantable plasmacytoma, TEPC-15 in BALB/c mice, induces a transient antibody response directed against the combining region of the myeloma protein produced by the tumor. Mice immunized with mitomycin-treated tumor cells produce similar antibody but do not develop tumor; mice so immunized survive longer than untreated mice when inoculated with viable TEPC-15 cells. This protection afforded by immunization can be transferred by serum alone; the protective effect of passively given serum is eliminated by absorbing out antibody directed against the myeloma protein.
D000373:Agglutinins / Q000032:analysis; D000818:Animals; D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D000951:Antigens, Neoplasm; D001666:Binding Sites, Antibody; D007108:Immune Tolerance; D007112:Immunity, Maternally-Acquired; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D008937:Mitomycins / Q000494:pharmacology; D009194:Myeloma Proteins / Q000097:blood; D010767:Phosphorylcholine / Q000276:immunology; D010954:Plasmacytoma / Q000276:immunology* / Q000401:mortality
D000373:Agglutinins; D000951:Antigens, Neoplasm; D008937:Mitomycins; D009194:Myeloma Proteins; D010767:Phosphorylcholine